2.50
Hdl Handle:
http://hdl.handle.net/10541/78353
Title:
Vaccine and antibody-directed T cell tumour immunotherapy.
Authors:
Dermime, Said; Gilham, David E; Shaw, David M; Davidson, Emma J; Meziane, El-Kahina; Armstrong, Anne C; Hawkins, Robert E; Stern, Peter L
Abstract:
Clearer evidence for immune surveillance in malignancy and the identification of many new tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted responses for therapy in cancer. The exploitation of active immunisation may be particularly favourable for TAA where tolerance is incomplete but passive immunisation may offer an additional strategy where the immune repertoire is affected by either tolerance or immune suppression. This review will consider how to utilise both active and passive types of therapy delivered by T cells in the context of the failure of tumour-specific immunity by presenting cancer patients. This article will outline the progress, problems and prospects of several different vaccine and antibody-targeted approaches for immunotherapy of cancer where proof of principle pre-clinical studies have been or will soon be translated into the clinic. Two examples of vaccination-based therapies where both T cell- and antibody-mediated anti-tumour responses are likely to be relevant and two examples of oncofoetal antigen-specific antibody-directed T cell therapies are described in the following sections: (1) therapeutic vaccination against human papillomavirus (HPV) antigens in cervical neoplasia; (2) B cell lymphoma vaccines including against immunoglobulin idiotype; (3) oncofoetal antigens as tumour targets for redirecting T cells with antibody strategies.
Affiliation:
Immunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK.
Citation:
Vaccine and antibody-directed T cell tumour immunotherapy. 2004, 1704 (1):11-35 Biochim. Biophys. Acta
Journal:
Biochimica et Biophysica Acta
Issue Date:
6-Jul-2004
URI:
http://hdl.handle.net/10541/78353
DOI:
10.1016/j.bbcan.2004.03.002
PubMed ID:
15238242
Type:
Article
Language:
en
ISSN:
0006-3002
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDermime, Said-
dc.contributor.authorGilham, David E-
dc.contributor.authorShaw, David M-
dc.contributor.authorDavidson, Emma J-
dc.contributor.authorMeziane, El-Kahina-
dc.contributor.authorArmstrong, Anne C-
dc.contributor.authorHawkins, Robert E-
dc.contributor.authorStern, Peter L-
dc.date.accessioned2009-08-24T14:08:30Z-
dc.date.available2009-08-24T14:08:30Z-
dc.date.issued2004-07-06-
dc.identifier.citationVaccine and antibody-directed T cell tumour immunotherapy. 2004, 1704 (1):11-35 Biochim. Biophys. Actaen
dc.identifier.issn0006-3002-
dc.identifier.pmid15238242-
dc.identifier.doi10.1016/j.bbcan.2004.03.002-
dc.identifier.urihttp://hdl.handle.net/10541/78353-
dc.description.abstractClearer evidence for immune surveillance in malignancy and the identification of many new tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted responses for therapy in cancer. The exploitation of active immunisation may be particularly favourable for TAA where tolerance is incomplete but passive immunisation may offer an additional strategy where the immune repertoire is affected by either tolerance or immune suppression. This review will consider how to utilise both active and passive types of therapy delivered by T cells in the context of the failure of tumour-specific immunity by presenting cancer patients. This article will outline the progress, problems and prospects of several different vaccine and antibody-targeted approaches for immunotherapy of cancer where proof of principle pre-clinical studies have been or will soon be translated into the clinic. Two examples of vaccination-based therapies where both T cell- and antibody-mediated anti-tumour responses are likely to be relevant and two examples of oncofoetal antigen-specific antibody-directed T cell therapies are described in the following sections: (1) therapeutic vaccination against human papillomavirus (HPV) antigens in cervical neoplasia; (2) B cell lymphoma vaccines including against immunoglobulin idiotype; (3) oncofoetal antigens as tumour targets for redirecting T cells with antibody strategies.en
dc.language.isoenen
dc.subjectUterine Cervical Canceren
dc.subjectTumour Escapeen
dc.subjectCanceren
dc.subject.meshAnimals-
dc.subject.meshAntibodies, Anti-Idiotypic-
dc.subject.meshAntigens, Neoplasm-
dc.subject.meshAntigens, Viral-
dc.subject.meshCancer Vaccines-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy, Active-
dc.subject.meshImmunotherapy, Adoptive-
dc.subject.meshLymphoma-
dc.subject.meshMice-
dc.subject.meshNeoplasms-
dc.subject.meshPapillomaviridae-
dc.subject.meshT-Lymphocytes, Cytotoxic-
dc.subject.meshTumor Escape-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleVaccine and antibody-directed T cell tumour immunotherapy.en
dc.typeArticleen
dc.contributor.departmentImmunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK.en
dc.identifier.journalBiochimica et Biophysica Actaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.